Camrelizumab plus famitinib in patients with advanced or metastatic kidney cancer

An ongoing phase 2 study of a combination of two new medicines, camrelizumab (an immune checkpoint inhibitor) and famitinib (a novel tyrosine kinase inhibitor that targets a number of kinases) is looking at the safety and effectiveness of this combination in people with advanced or metastatic clear cell renal cell carcinoma (RCC). Previously treated people […]

read more

Treatment with stereotactic body radiotherapy plus TKIs or immunotherapy is safe and may improve survival of metastatic kidney cancer patients

Two small studies looked at the addition of a type of radiotherapy treatment, called stereotactic body radiotherapy (SBRT), to treatment with a tyrosine kinase inhibitor (TKI), such as sunitinib or pazopanib, or a checkpoint inhibitor, such as nivolumab for patients with metastatic renal cell carcinoma (RCC). In the first study, 56 patients with metastatic RCC […]

read more

Potential prognostic biomarker for kidney cancer

A recent study, published in the European Review for Medical and Pharmacological Sciences last month, identified tyrosine kinase receptor (TEK) as a potential novel prognostic biomarker for clear cell renal cell carcinoma (ccRCC). TEK is a protein receptor found on the surface of tumour cells. It plays an important role in the growth of new […]

read more
Showing all 3 results